{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:20:49Z","timestamp":1775492449071,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10741-020-10029-x","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T12:03:31Z","timestamp":1601467411000},"page":"355-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hemodynamic effects of ivabradine use in combination with intravenous inotropic therapy in advanced heart failure"],"prefix":"10.1007","volume":"26","author":[{"given":"Mohammed","family":"Elzeneini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Juan M.","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan R.","family":"Vilaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"10029_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ejheart.2007.04.003","volume":"9","author":"M Metra","year":"2007","unstructured":"Metra M, Ponikowski P, Dickstein K, McMurray JJV, Gavazzi A, Bergh C-H et al (2007) Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 9:684\u2013694. https:\/\/doi.org\/10.1016\/j.ejheart.2007.04.003","journal-title":"Eur J Heart Fail"},{"key":"10029_CR2","doi-asserted-by":"publisher","unstructured":"Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al (2009) 2009 focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the Aamerican College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192065","DOI":"10.1161\/CIRCULATIONAHA.109.192065"},{"key":"10029_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.jacc.2013.05.020","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Chair V, Bozkurt B, Butler J, Casey DE et al (2013) 2013 ACCF\/AHA Guideline for the management of\u00a0heart\u00a0failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. JAC 62:1495\u20131539. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.020","journal-title":"JAC"},{"key":"10029_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mhj.2003.50","volume":"145","author":"JM Aranda","year":"2003","unstructured":"Aranda JM, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS et al (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145:324\u2013329. https:\/\/doi.org\/10.1067\/mhj.2003.50","journal-title":"Am Heart J"},{"key":"10029_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.healun.2003.08.017","volume":"23","author":"SC Brozena","year":"2004","unstructured":"Brozena SC, Twomey C, Goldberg LR, Desai SS, Drachman B, Kao A et al (2004) A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant 23:1082\u20131086. https:\/\/doi.org\/10.1016\/j.healun.2003.08.017","journal-title":"J Heart Lung Transplant"},{"key":"10029_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1054\/jcaf.2003.24","volume":"9","author":"RE Hershberger","year":"2003","unstructured":"Hershberger RE, Nauman D, Walker TL, Dutton D, Burgess D (2003) Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 9:180\u2013187. https:\/\/doi.org\/10.1054\/jcaf.2003.24","journal-title":"J Card Fail"},{"key":"10029_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jchf.2018.03.019","volume":"6","author":"T Nizamic","year":"2018","unstructured":"Nizamic T, Murad MH, Allen LA, McIlvennan CK, Wordingham SE, Matlock DD et al (2018) Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis. JACC Hear Fail 6:757\u2013767. https:\/\/doi.org\/10.1016\/j.jchf.2018.03.019","journal-title":"JACC Hear Fail"},{"key":"10029_CR8","doi-asserted-by":"publisher","first-page":"1096.e1","DOI":"10.1016\/j.ahj.2006.08.003","volume":"152","author":"PJ Hauptman","year":"2006","unstructured":"Hauptman PJ, Mikolajczak P, George A, Mohr CJ, Hoover R, Swindle J et al (2006) Chronic inotropic therapy in end-stage heart failure. Am Heart J 152:1096.e1\u20131096.e8. https:\/\/doi.org\/10.1016\/j.ahj.2006.08.003","journal-title":"Am Heart J"},{"key":"10029_CR9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1053\/jcan.2001.23274","volume":"15","author":"RO Feneck","year":"2001","unstructured":"Feneck RO, Sherry KM, Withington PS, Oduro-Dominah A (2001) Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery. J Cardiothorac Vasc Anesth 15:306\u2013315. https:\/\/doi.org\/10.1053\/jcan.2001.23274","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10029_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","volume":"287","author":"MS Cuffe","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS et al (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. J Am Med Assoc 287:1541\u20131547. https:\/\/doi.org\/10.1001\/jama.287.12.1541","journal-title":"J Am Med Assoc"},{"key":"10029_CR11","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"GM Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997\u20131003. https:\/\/doi.org\/10.1016\/S0735-1097(02)02968-6","journal-title":"J Am Coll Cardiol"},{"key":"10029_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s0002-8703(99)70250-4","volume":"138","author":"CM O\u2019Connor","year":"1999","unstructured":"O\u2019Connor CM, Gattis WA, Uretsky BF, Adams KF, McNulty SE, Grossman SH et al (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138:78\u201386. https:\/\/doi.org\/10.1016\/s0002-8703(99)70250-4","journal-title":"Am Heart J"},{"key":"10029_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2006.09.005","volume":"153","author":"U Elkayam","year":"2007","unstructured":"Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW et al (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153:98\u2013104. https:\/\/doi.org\/10.1016\/j.ahj.2006.09.005","journal-title":"Am Heart J"},{"key":"10029_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","volume":"46","author":"WT Abraham","year":"2005","unstructured":"Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, Lejemtel TH et al (2005) In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46:57\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2005.03.051","journal-title":"J Am Coll Cardiol"},{"key":"10029_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/ejhf.991","volume":"20","author":"A Mebazaa","year":"2018","unstructured":"Mebazaa A, Motiejunaite J, Gayat E, Crespo-Leiro MG, Lund LH, Maggioni AP et al (2018) Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail 20:332\u2013341. https:\/\/doi.org\/10.1002\/ejhf.991","journal-title":"Eur J Heart Fail"},{"key":"10029_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, \u00c9des I, Fruhwald S, De Hert SG, Salmenper\u00e4 M, Leppikangas H et al (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159:82\u201387. https:\/\/doi.org\/10.1016\/j.ijcard.2011.07.022","journal-title":"Int J Cardiol"},{"key":"10029_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/ehf2.12177","volume":"4","author":"S Silvetti","year":"2017","unstructured":"Silvetti S, Belletti A, Fontana A, Pollesello P (2017) Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Hear Fail 4:595\u2013604. https:\/\/doi.org\/10.1002\/ehf2.12177","journal-title":"ESC Hear Fail"},{"key":"10029_CR18","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Com\u00edn-Colet","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garc\u00eda Pinilla JM, Almenar L et al (2018) Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail 20:1128\u20131136. https:\/\/doi.org\/10.1002\/ejhf.1145","journal-title":"Eur J Heart Fail"},{"key":"10029_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2015.08.188","volume":"202","author":"S Silvetti","year":"2016","unstructured":"Silvetti S, Nieminen MS (2016) Repeated or intermittent levosimendan treatment in advanced heart failure: an updated meta-analysis. Int J Cardiol 202:138\u2013143. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.188","journal-title":"Int J Cardiol"},{"key":"10029_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijcard.2016.02.014","volume":"209","author":"P Pollesello","year":"2016","unstructured":"Pollesello P, Parissis J, Kivikko M, Harjola VP (2016) Levosimendan meta-analyses: is there a pattern in the effect on mortality? Int J Cardiol 209:77\u201383. https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.014","journal-title":"Int J Cardiol"},{"key":"10029_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JGF, Just H, Papp JGY, Scholz H, Peuhkurinen K et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(02)09455-2","journal-title":"Lancet"},{"key":"10029_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ijcard.2011.03.013","volume":"159","author":"MJ Bonios","year":"2012","unstructured":"Bonios MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN et al (2012) Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 159:225\u2013229. https:\/\/doi.org\/10.1016\/j.ijcard.2011.03.013","journal-title":"Int J Cardiol"},{"key":"10029_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ehf2.12366","volume":"6","author":"G P\u00f6lzl","year":"2019","unstructured":"P\u00f6lzl G, Allipour Birgani S, Com\u00edn-Colet J, Delgado JF, Fedele F, Garc\u00eda-Gonz\u00e1les MJ et al (2019) Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Hear Fail 6:174\u2013181. https:\/\/doi.org\/10.1002\/ehf2.12366","journal-title":"ESC Hear Fail"},{"key":"10029_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","volume":"1","author":"M Packer","year":"2013","unstructured":"Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J et al (2013) Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Hear Fail 1:103\u2013111. https:\/\/doi.org\/10.1016\/j.jchf.2012.12.004","journal-title":"JACC Hear Fail"},{"key":"10029_CR25","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. J Am Med Assoc 297:1883\u20131891. https:\/\/doi.org\/10.1001\/jama.297.17.1883","journal-title":"J Am Med Assoc"},{"key":"10029_CR26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592","journal-title":"Eur J Heart Fail"},{"key":"10029_CR27","doi-asserted-by":"publisher","first-page":"H1884","DOI":"10.1152\/ajpheart.1993.265.6.H1884","volume":"265","author":"JL Vanoverschelde","year":"1993","unstructured":"Vanoverschelde JL, Wijns W, Essamri B, Bol A, Robert A, Labar D et al (1993) Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Phys 265:H1884\u2013H1892. https:\/\/doi.org\/10.1152\/ajpheart.1993.265.6.H1884","journal-title":"Am J Phys"},{"key":"10029_CR28","doi-asserted-by":"publisher","unstructured":"Motwani M, Kidambi A, Sourbron S, Fairbairn TA, Uddin A, Kozerke S et al (2014) Quantitative three-dimensional cardiovascular magnetic resonance myocardial perfusion imaging in systole and diastole. J Cardiovasc Magn Reson 16. https:\/\/doi.org\/10.1186\/1532-429X-16-19","DOI":"10.1186\/1532-429X-16-19"},{"key":"10029_CR29","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1161\/01.cir.0000023042.50192.f4","volume":"106","author":"B Pieske","year":"2002","unstructured":"Pieske B, Maier LS, Piacentino V, Weisser J, Hasenfuss G, Houser S (2002) Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation 106:447\u2013453. https:\/\/doi.org\/10.1161\/01.cir.0000023042.50192.f4","journal-title":"Circulation"},{"key":"10029_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jchf.2017.09.018","volume":"6","author":"J Gierula","year":"2018","unstructured":"Gierula J, Paton MF, Lowry JE, Jamil HA, Byrom R, Drozd M et al (2018) Rate-response programming tailored to the force-frequency relationship improves exercise tolerance in chronic heart failure. JACC Hear Fail 6:105\u2013113. https:\/\/doi.org\/10.1016\/j.jchf.2017.09.018","journal-title":"JACC Hear Fail"},{"key":"10029_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","volume":"101","author":"G Flannery","year":"2008","unstructured":"Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101:865\u2013869. https:\/\/doi.org\/10.1016\/j.amjcard.2007.11.023","journal-title":"Am J Cardiol"},{"key":"10029_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/s0735-1097(02)02134-4","volume":"40","author":"M Metra","year":"2002","unstructured":"Metra M, Nodari S, D\u2019Aloia A, Muneretto C, Robertson AD, Bristow MR et al (2002) Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 40:1248\u20131258. https:\/\/doi.org\/10.1016\/s0735-1097(02)02134-4","journal-title":"J Am Coll Cardiol"},{"key":"10029_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1085\/jgp.20028593","volume":"120","author":"A Bucchi","year":"2002","unstructured":"Bucchi A, Baruscotti M, Difrancesco D (2002) Current-dependent block of rabbit sino-atrial node If channels by ivabradine. J Gen Physiol 120:1\u201313. https:\/\/doi.org\/10.1085\/jgp.20028593","journal-title":"J Gen Physiol"},{"key":"10029_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1113\/jphysiol.2005.100776","volume":"572","author":"A Bucchi","year":"2006","unstructured":"Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D (2006) Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol 572:335\u2013346. https:\/\/doi.org\/10.1113\/jphysiol.2005.100776","journal-title":"J Physiol"},{"key":"10029_CR35","doi-asserted-by":"crossref","unstructured":"Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR (2017) The clinical use of ivabradine","DOI":"10.1016\/j.jacc.2017.08.038"},{"key":"10029_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000073933","volume":"100","author":"M Manz","year":"2003","unstructured":"Manz M, Reuter M, Lauck G, Omran H, Jung W (2003) A single intravenous dose of ivabradine, a (novel If inhibitor, lowers heart rate but does) not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100:149\u2013155. https:\/\/doi.org\/10.1159\/000073933","journal-title":"Cardiology"},{"key":"10029_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.yjmcc.2011.09.005","volume":"51","author":"S Herrmann","year":"2011","unstructured":"Herrmann S, Layh B, Ludwig A (2011) Novel insights into the distribution of cardiac HCN channels: an expression study in the mouse heart. J Mol Cell Cardiol 51:997\u20131006. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.09.005","journal-title":"J Mol Cell Cardiol"},{"key":"10029_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/jpet.103.059717","volume":"308","author":"P Colin","year":"2004","unstructured":"Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A (2004) Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther 308:236\u2013240. https:\/\/doi.org\/10.1124\/jpet.103.059717","journal-title":"J Pharmacol Exp Ther"},{"key":"10029_CR39","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","volume":"109","author":"P Mulder","year":"2004","unstructured":"Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F et al (2004) Long-term heart rate reduction induced by the selective if current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109:1674\u20131679. https:\/\/doi.org\/10.1161\/01.CIR.0000118464.48959.1C","journal-title":"Circulation"},{"key":"10029_CR40","doi-asserted-by":"publisher","unstructured":"Dedkov EI, Zheng W, Christensen LP, Weiss RM, Mahlberg-Gaudin F, Tomanek RJ (2007) Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol 293. https:\/\/doi.org\/10.1152\/ajpheart.00047.2007","DOI":"10.1152\/ajpheart.00047.2007"},{"key":"10029_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/FJC.0b013e31823e5e01","volume":"59","author":"Y Fang","year":"2012","unstructured":"Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F et al (2012) Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 59:260\u2013267. https:\/\/doi.org\/10.1097\/FJC.0b013e31823e5e01","journal-title":"J Cardiovasc Pharmacol"},{"key":"10029_CR42","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875\u2013885. https:\/\/doi.org\/10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"10029_CR43","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2013.07.027","volume":"62","author":"JC Reil","year":"2013","unstructured":"Reil JC, Tardif JC, Ford I, Lloyd SM, O\u2019Meara E, Komajda M et al (2013) Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 62:1977\u20131985. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.027","journal-title":"J Am Coll Cardiol"},{"key":"10029_CR44","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"J-C Tardif","year":"2011","unstructured":"Tardif J-C, O\u2019Meara E, Komajda M, B\u00f6hm M, Borer JS, Ford I et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32:2507\u20132515","journal-title":"Eur Heart J"},{"key":"10029_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/apha.12704","volume":"218","author":"JP Bakkehaug","year":"2016","unstructured":"Bakkehaug JP, N\u00e6sheim T, Torgersen Engstad E, Kildal AB, Myrmel T, How OJ (2016) Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction. Acta Physiol 218:78\u201388. https:\/\/doi.org\/10.1111\/apha.12704","journal-title":"Acta Physiol"},{"key":"10029_CR46","doi-asserted-by":"publisher","first-page":"e13879","DOI":"10.14814\/phy2.13879","volume":"6","author":"L R\u00f8nning","year":"2018","unstructured":"R\u00f8nning L, Bakkehaug JP, R\u00f8dland L, Kildal AB, Myrmel T, How OJ (2018) Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. Phys Rep 6:e13879. https:\/\/doi.org\/10.14814\/phy2.13879","journal-title":"Phys Rep"},{"key":"10029_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5603\/CJ.a2018.0078","volume":"27","author":"MP Izco","year":"2020","unstructured":"Izco MP, Ram\u00edrez-Carracedo R, Navarro IH, Ruiz \u00c1O, Navarro BC, Berrocal IC et al (2020) Ivabradine in acute heart failure: effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial. Cardiol J 27:62\u201371. https:\/\/doi.org\/10.5603\/CJ.a2018.0078","journal-title":"Cardiol J"},{"key":"10029_CR48","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","volume":"10","author":"GM De Ferrari","year":"2008","unstructured":"De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C et al (2008) Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure\u2606. Eur J Heart Fail 10:550\u2013555. https:\/\/doi.org\/10.1016\/j.ejheart.2008.04.005","journal-title":"Eur J Heart Fail"},{"key":"10029_CR49","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2459\/JCM.0000000000000033","volume":"16","author":"Y Cavusoglu","year":"2015","unstructured":"Cavusoglu Y, Mert U, Nadir A, Mutlu F, Morrad B, Ulus T (2015) Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. J Cardiovasc Med 16:603\u2013609. https:\/\/doi.org\/10.2459\/JCM.0000000000000033","journal-title":"J Cardiovasc Med"},{"key":"10029_CR50","doi-asserted-by":"publisher","first-page":"786","DOI":"10.5603\/KP.a2017.0094","volume":"75","author":"KU Mert","year":"2017","unstructured":"Mert KU, Mert G\u00d6, Morrad B, Tahmazov S, Mutlu F, \u00c7avu\u015foglu Y (2017) Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias. Kardiol Pol 75:786\u2013793. https:\/\/doi.org\/10.5603\/KP.a2017.0094","journal-title":"Kardiol Pol"},{"key":"10029_CR51","doi-asserted-by":"publisher","unstructured":"Porcile R, Levin R (2016) Safety, tolerability and efficacy of ivabradine for control of sinus tachycardia in patients undergoing inotropic therapy. Curr Res Cardiol 3. https:\/\/doi.org\/10.4172\/2368-0512.1000056","DOI":"10.4172\/2368-0512.1000056"},{"key":"10029_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13054-018-2124-8","volume":"22","author":"LS Nguyen","year":"2018","unstructured":"Nguyen LS, Squara P, Amour J, Carbognani D, Bouabdallah K, Thierry S et al (2018) Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial. Crit Care 22:193. https:\/\/doi.org\/10.1186\/s13054-018-2124-8","journal-title":"Crit Care"},{"key":"10029_CR53","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijcard.2014.07.093","volume":"176","author":"R Gallet","year":"2014","unstructured":"Gallet R, Ternacle J, Damy T, Guendouz S, Bremont C, Seemann A et al (2014) Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol 176:450\u2013455. https:\/\/doi.org\/10.1016\/j.ijcard.2014.07.093","journal-title":"Int J Cardiol"},{"key":"10029_CR54","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ehf2.12499","volume":"6","author":"MH Chiu","year":"2019","unstructured":"Chiu MH, Howlett JG, Sharma NC (2019) Initiation of ivabradine in cardiogenic shock. ESC Hear Fail 6:1088\u20131091. https:\/\/doi.org\/10.1002\/ehf2.12499","journal-title":"ESC Hear Fail"},{"key":"10029_CR55","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.healun.2016.06.005","volume":"35","author":"MS Lofrano-Alves","year":"2016","unstructured":"Lofrano-Alves MS, Issa VS, Biselli B, Chizzola P, Ayub-Ferreira SM, Bocchi EA (2016) Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): a randomized, double-blind, placebo-controlled trial. J Heart Lung Transplant 35:1260\u20131264. https:\/\/doi.org\/10.1016\/j.healun.2016.06.005","journal-title":"J Heart Lung Transplant"},{"key":"10029_CR56","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/SHK.0000000000000992","volume":"49","author":"S Nuding","year":"2018","unstructured":"Nuding S, Schr\u00f6der J, Presek P, Wienke A, M\u00fcller-Werdan U, Ebelt H et al (2018) Reducing elevated heart rates in patients with multiple organ dysfunction syndrome with the i f (Funny Channel Current) Inhibitor Ivabradine. Shock 49:402\u2013411. https:\/\/doi.org\/10.1097\/SHK.0000000000000992","journal-title":"Shock"},{"key":"10029_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.bjp.0706998","volume":"150","author":"L Cervetto","year":"2007","unstructured":"Cervetto L, Demontis GC, Gargini C (2007) Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol 150:383\u2013390. https:\/\/doi.org\/10.1038\/sj.bjp.0706998","journal-title":"Br J Pharmacol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10029-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-10029-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10029-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T02:23:03Z","timestamp":1632968583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-10029-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10029"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-10029-x","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]},"assertion":[{"value":"15 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}